ZBH Zimmer Biomet Stock Outlook 2026: Aging Demographics Meet Surgical Robotics

Orthopedic surgery is one of the few industries that can look at a population pyramid and read its revenue forecast directly. The roughly 76 million Americans born between 1946 and 1964 are moving through their peak joint replacement years. Zimmer Biomet (ZBH) holds a leading position in the two procedures — knee and hip replacement — that will perform most of that work over the next decade.

This is not a discovery story. The demographic thesis is widely understood and widely owned. The question for 2026 is whether ZBH’s ROSA surgical robot is climbing fast enough to close the gap on Stryker’s Mako — and whether that robotics execution unlocks a valuation premium on top of the already-solid volume growth. This analysis examines both floors and ceilings.

---

The Business in Plain Terms

ZBH’s revenue model is elemental: when a surgeon replaces a knee or hip, they use an implant kit. ZBH sells the kit. No subscription ambiguity, no platform re-contracting, no software licensing debate — just procedure volume times average kit price. Understanding this simplicity is prerequisite to understanding why the stock behaves the way it does.

Knee reconstruction is the largest segment. Total and partial knee replacements account for the plurality of ZBH’s revenue. The typical patient is in their mid-sixties to mid-seventies, suffering from osteoarthritis that has degraded cartilage beyond conservative treatment options. At that stage, surgery is not elective in the way cosmetic procedures are — it is elective in the sense that the patient could technically avoid it, but the quality-of-life consequence is severe.

Hip reconstruction follows essentially the same demographic profile. Total hip arthroplasty is one of the most commonly performed elective surgical procedures in the US, and outcomes data is among the strongest in all of elective medicine. An elderly patient whose hip has been successfully replaced can walk, exercise moderately, and maintain independence — clinical outcomes that insurers and Medicare cover readily because they reduce downstream care costs.

ROSA surgical robotics is the growth accelerant. ROSA Knee and ROSA Hip provide computer-assisted planning and robotic guidance that, in theory, improves implant positioning accuracy compared to manual techniques. Beyond clinical benefit, the business logic is compelling: a hospital that installs ROSA becomes a structural ZBH implant customer. The robot requires ZBH implant kits to function optimally — that lock-in effect is what separates a robotics business from a pure capital equipment play.

The ZimVie divestiture context matters. In 2022, ZBH completed the spinoff of ZimVie, which carries the spine and dental implant businesses. The rationale was straightforward: spine and dental have lower margins, different competitive dynamics, and different growth profiles than joint reconstruction. Separating them allowed ZBH to present a cleaner investment story and reallocate R&D and commercial resources toward robotics-enhanced joint reconstruction — the highest-margin, highest-multiple part of the portfolio.

---

Why the Demographic Floor Is Real and Multi-Decade

The aging argument for orthopedics gets cited so frequently it risks becoming noise. It should not. The numbers behind it are not projections — they are people who already exist and are aging on a known schedule.

The 65-to-74 age bracket — where knee and hip replacement incidence is highest — continues expanding in the US through the mid-2030s. Roughly 10,000 Americans turn 65 every day, a rate that does not abate for another decade. European demographic curves are structurally similar, with Germany, Italy, France, and the UK all showing the same baby boom cohort aging into peak procedure years.

The obesity comorbidity layer extends the thesis beyond pure age demographics. Higher body-mass-index correlates directly with accelerated cartilage degradation and earlier onset of symptomatic osteoarthritis. As US obesity prevalence remains elevated — and rises in a number of other countries — the effective “eligible for joint replacement” population grows faster than age-based projections alone would suggest.

The recession resistance of this demand deserves specific emphasis, because it is what distinguishes ZBH from most other medical device companies. Consider the patient decision framework: a 68-year-old with bone-on-bone knee pain who cannot walk to their mailbox is not going to cancel surgery because the S&P 500 dropped 15%. They might delay by a month or two — which creates short-term quarterly noise — but the procedure backlog quickly re-absorbs. The few instances of meaningful demand disruption (COVID-19 hospital restrictions being the clearest example) were followed by demand surges as pent-up patients returned.

This demand permanence is fundamentally different from GPN’s payment volume exposure, which tracks consumer spending sentiment. See the Global Payments (GPN) Stock Outlook 2026 for the contrast.

---

ROSA vs. Mako: An Honest Assessment of Where ZBH Stands

The single most important competitive fact about ZBH’s robotics program: Stryker’s Mako is the market leader, and it got there first.

Mako entered the orthopedic robotics market through Stryker’s 2013 acquisition of MAKO Surgical. By the time ZBH launched ROSA Knee commercially, Mako already had hundreds of hospitals committed to its platform, surgeons trained on its workflow, and service relationships in place. First-mover advantage in surgical robotics is particularly durable because training a surgeon on a robotic platform — and then expecting them to switch — is a high-friction, high-stakes request.

ROSA’s response to that first-mover disadvantage has been primarily architectural: an open platform that can theoretically support implants from multiple manufacturers, giving hospital procurement committees an argument for flexibility. In practice, most hospitals running ROSA still skew heavily toward ZBH implants — the commercial incentives align that way — but the open-platform design occasionally breaks tie-breaker decisions in ZBH’s favor.

The clinical differentiation between ROSA and Mako is genuinely ambiguous. Both platforms offer pre-surgical imaging analysis, intraoperative guidance, and real-time feedback on implant positioning. The peer-reviewed literature does not clearly crown either as superior — which means the competition is largely being won on commercial factors: salesperson relationships, service agreements, upgrade pricing, and training support.

Platform	Company	Installed Base Status
Mako	Stryker	Market leader — broadest surgeon familiarity
ROSA	Zimmer Biomet	Challenger — open platform architecture
Velys	J&J DePuy	Leveraging J&J distribution scale
CORI	Smith+Nephew	Value positioning in smaller markets

For ZBH, the robotics question is not whether ROSA is a good product — it is good enough. The question is whether the pace of ROSA installations is closing the gap with Mako fast enough to justify a robotics-company premium in the stock, or whether ZBH is perpetually the strong number two that never quite challenges the leader’s economics.

---

Bull Case: Three Drivers with Genuine Staying Power

Demographic volume growth is the base compounding engine. ZBH does not need to outgrow its market or take share from Stryker to compound shareholders’ money. If the market grows at the low-to-mid single-digit rates that demographic math and obesity trends support, and ZBH maintains its share within that market, the revenue and earnings per share grow predictably. That predictability is valuable, particularly in a portfolio context.

ROSA penetration drives ASP expansion on top of volume. Robotic knee replacement cases use more sophisticated, higher-priced implant kits than manual cases — both because the robotic procedure enables more precise bone preparation that certain implant designs require, and because hospitals willing to invest in a robot tend to be invested in the premium segment of the procedure market. As ROSA’s share of ZBH’s total case volume rises, the average revenue per case rises with it, even if volume growth remains at demographic baseline rates. This creates a natural earnings lever beyond the market growth rate.

Portfolio simplification improves operational execution. Management teams that run two or three businesses with fundamentally different customer profiles, sales cycles, and competitive dynamics inevitably make compromises that serve no business optimally. The ZimVie separation removed those compromises for ZBH. R&D investment in ROSA does not have to compete with spine innovation budgets. The commercial team can be organized entirely around orthopedic surgeons and hospital system procurement. That focus should translate into better execution against Stryker over a three-to-five year period.

---

Bear Case: Three Scenarios Where the Investment Thesis Fails

Mako entrenches through large system agreements. If major hospital systems — Ascension, HCA, CommonSpirit — sign multi-year Mako upgrade agreements covering their entire orthopedic programs, ZBH loses access to those systems’ case volume for the contract duration. Robot purchasing in healthcare tends to be institution-wide rather than surgeon-by-surgeon, so one large system agreement against ZBH effectively locks out hundreds of ROSA cases per year. The pace of system-level Mako commitments is the hardest thing to track from outside the company.

China VBP continues compressing margins. China’s Volume-Based Procurement policy for medical devices has already forced severe ASP reductions in orthopedic implants — reductions of 80% or more in some categories in previous bidding rounds. ZBH’s China revenue is structurally exposed to further rounds. The difficult tradeoff: refusing to participate in VBP bidding means losing hospital access in the world’s largest population. Accepting VBP terms maintains volume but at margins that may not justify the capital deployed. ZBH’s China strategy is navigating between those two unpleasant options, and there is no obviously correct answer.

Post-COVID catch-up demand normalizes and exposes underlying growth rate. Procedure volumes surged during 2022-2023 as patients who had deferred joint replacements during COVID returned to hospitals simultaneously. That pent-up demand baked an above-trend growth rate into ZBH’s reported numbers for several quarters. As the catch-up normalizes, the underlying demographic growth rate becomes the baseline again — and if the underlying rate is at the low end of what the market has priced, earnings estimates require revision.

---

How the Implant Industry’s Pricing Model Works — And Why It Matters

A nuance that matters for ZBH’s investment thesis: the way implant pricing works in the US healthcare system creates different pressures than most investors expect.

ZBH does not set a price and sell implants to hospitals like a consumer goods company. Instead:

1. Large hospital systems and independent hospitals belong to Group Purchasing Organizations (GPOs) — cooperative purchasing groups that negotiate contracts with device manufacturers on behalf of their members.
2. GPO contracts set price ceilings and committed volume requirements. ZBH negotiates these contracts for the right to sell into GPO member hospitals.
3. Surgeons within those hospitals retain some influence — they may have loyalty to ZBH implant designs — but procurement increasingly routes through GPO contract terms.

As hospital system consolidation continues — more hospitals joining fewer, larger health systems — the GPO negotiating leverage against implant manufacturers grows. This is a structural headwind on ZBH’s pricing power that is independent of competition from Stryker or Smith+Nephew. It is simply the downstream effect of hospital consolidation that the entire orthopedic implant industry faces.

ROSA matters in this context because robot-assisted procedures can justify ASP premiums that GPO contracts may allow as exceptions for robotic implant systems — another reason the ROSA penetration story is intertwined with the pricing story.

---

How Orthopedic Sales Actually Work: The Surgeon Relationship Model

A nuance critical to evaluating ZBH’s competitive durability: orthopedic implants are not purchased like commodity supplies. The surgeon relationship is the commercial foundation of the entire industry.

When a hospital purchases implant systems, the decision involves multiple parties:

• The surgeon has strong preferences based on training, familiarity with specific implant geometries, and clinical outcomes data they trust. A surgeon who trained on ZBH’s implant system during residency and has performed hundreds of procedures with that system is deeply reluctant to switch.
• The hospital procurement department and GPO (Group Purchasing Organization) negotiate pricing and preferred vendor status, but cannot unilaterally override surgeon preferences without risking quality-of-care issues.
• The OR nursing and technician staff builds institutional knowledge around specific implant systems — setting up ZBH trays differently than Stryker trays, knowing which instruments pair with which implant generations.

This three-way dynamic creates a switching cost structure that is much stickier than a typical enterprise software contract. Convincing a surgeon to change implant systems requires not just demonstrating clinical equivalence or superiority in ROSA, but also overcoming the psychological resistance to relearning something they already do with high confidence.

For ZBH, this means the sales cycle for converting a Stryker surgeon to ROSA/ZBH systems is long, relationship-intensive, and depends on building trust through clinical evidence, training programs, and consistent device performance. It is not a scalable digital acquisition funnel — it is a field sales model that requires investment and patience. This explains why new robotic platforms take years to gain meaningful share even when the technology is competitive.

---

The Aging Population Thesis Across Different Healthcare Systems

The demographic tailwind for joint replacement is global, but the translation into ZBH revenue varies by healthcare system in ways worth understanding.

United States — Medicare-Driven: Medicare covers the majority of joint replacements in the US, since most patients are over 65. Medicare sets reimbursement rates by DRG (Diagnosis Related Group), which indirectly constrains how much hospitals can pay for implants without operating at a loss on the procedure. This is a managed pricing environment, not a free market for implant pricing. ZBH navigates this through GPO contracts and the robotics-premium argument.

Germany and Western Europe — Social Insurance Systems: Germany’s GKV (statutory health insurance) covers joint replacements with regional hospital cost benchmarks. Hospital systems negotiate implant prices directly within budget allocations from the insurance funds. Margins can be better or worse than the US depending on the specific country and hospital negotiating leverage. ZBH’s European business benefits from aging demographics similar to the US but faces different pricing structures.

Japan — Aging at Extreme Pace: Japan has the world’s oldest large economy. The proportion of the population over 65 is higher than any major market ZBH serves. Joint replacement volume in Japan is still lower than comparable Western markets relative to the eligible population, suggesting structural growth runway — but Japanese pricing controls through the MHLW (Ministry of Health, Labour and Welfare) create challenging economics for premium implant pricing.

China — VBP Disruption: Discussed in the bear case above. The VBP system has fundamentally changed the Chinese orthopedic implant economics. ZBH must decide where to compete on price vs. where to pursue premium positioning for complex cases that may receive VBP exceptions.

Understanding this geographic revenue mix is essential for evaluating how ZBH’s total growth rate decomposes — and where future growth is most likely to come from.

---

Competitor Comparison for Medical Device Portfolio Building

Company	Primary Focus	Direct Orthopedic Overlap with ZBH
Stryker (SYK)	Ortho + MedSurg + Neurotechnology	Direct — closest comp, primary ROSA adversary
J&J DePuy Synthes	Ortho + Spine + Trauma	Direct in reconstruction; diffused by larger J&J portfolio
Smith+Nephew	Ortho + Sports Medicine + Wound	Direct but smaller scale in major reconstruction
Medtronic (MDT)	Cardiac + Neuro + Diabetes + Spine	Tangential — spine overlap, minimal joint reconstruction
Boston Scientific (BSX)	Cardiology + Urology + Endoscopy	Not an orthopedic competitor

Stryker (SYK) is both the benchmark and the cautionary tale for ZBH investors. Stryker consistently trades at a premium multiple to ZBH — the market pays for Mako’s leadership position, Stryker’s diversified MedSurg business, and management’s execution track record. The gap between Stryker’s multiple and ZBH’s multiple is the quantification of what “second place in orthopedic robotics” costs investors. Closing that gap, or at least narrowing it, is the thesis.

Medtronic (MDT) offers a different lesson: a mega-cap device company that tried to be everything in healthcare and has faced persistent criticism for lack of focus. ZBH’s post-ZimVie sharpening is, in part, a response to the Medtronic model’s critics. Focused beats diversified in device execution — at least in theory.

Boston Scientific (BSX) operates in entirely different anatomy. It competes for investor capital in the “medical devices” category but does not touch orthopedics. It belongs in a separate analytical bucket.

---

The Biomet History: Why ZBH’s Balance Sheet Looks the Way It Does

Understanding ZBH’s financial structure requires going back to 2015, when Zimmer Holdings merged with Biomet in a roughly $13.4 billion transaction. The combined entity was renamed Zimmer Biomet Holdings. That merger created the company’s current scale in knee and hip reconstruction — but it also layered on substantial acquisition-related goodwill and intangible assets, along with a significant debt load.

The practical implications for investors:

Goodwill and intangibles on the balance sheet are being amortized over time. This amortization is a non-cash charge that depresses GAAP earnings significantly relative to adjusted earnings. When ZBH reports “adjusted operating earnings,” it is primarily adding back this amortization. The adjusted figure is the more economically meaningful metric for evaluating ongoing business performance — but it requires understanding that the reported GAAP number carries legacy acquisition accounting that does not reflect the underlying cash generation of the business.

Debt from the Biomet acquisition has been reduced over subsequent years through free cash flow generation, but ZBH still carries meaningful leverage. The debt level constrains ZBH’s ability to make large acquisitions — which explains why the strategic focus has been organic growth in robotics rather than transformative M&A. It also means that any significant free cash flow shortfall creates more strain than it would for a net-cash company.

The ZimVie spinoff in 2022 also affected the debt structure — the separation allocated some debt to ZimVie, giving ZBH a slightly cleaner balance sheet post-spinoff. But the Biomet legacy still shapes the reported financials in ways that require adjustment before comparison to peers like Stryker, which has a different acquisition history.

This balance sheet context matters when reading ZBH’s reported results: always compare Adjusted EBITDA and Adjusted EPS to Stryker’s equivalent adjusted metrics, not GAAP to GAAP. The GAAP comparison will systematically mislead.

---

ZBH vs. GPN: Portfolio Contrast

Global Payments (GPN) represents nearly the opposite portfolio characteristic from ZBH. GPN’s revenue is a function of consumer spending volume — which compresses in recessions. ZBH’s revenue is a function of how many knees wear out — which does not follow a business cycle.

In a diversified portfolio, holding both creates a useful balance: technology/financial cyclicality from GPN offset by demographic defensiveness from ZBH. The two stories are entirely independent at the operational level, which is the point.

---

Free Cash Flow and Capital Allocation: Where the Money Goes

ZBH generates meaningful free cash flow from its implant business — the revenue model (units sold × price per kit) is operationally capital-light once the commercial infrastructure is established. Understanding where that cash flows reveals management priorities and constraints.

Debt service takes priority. The Biomet acquisition legacy created a debt load that ZBH has been methodically reducing. Investors should track net debt and leverage ratios over time — declining leverage signals both financial health and eventual flexibility to return more capital to shareholders.

ROSA investment — capital expenditures for manufacturing ROSA systems and continuing R&D — is the strategic spending priority. Robotic system manufacturing has higher capital intensity than implant manufacturing. As ZBH scales ROSA production, capex requirements remain elevated. Management has indicated that robotics investment will remain a priority, which means free cash flow available for other uses is constrained until ROSA reaches sufficient production scale efficiency.

Share buybacks operate as a residual capital return mechanism at ZBH — after debt service and strategic investment, remaining free cash flow funds repurchases. The pace of buybacks has varied with debt reduction priorities and available capital. Watch for guidance on buyback authorization and pace as indicators of management’s confidence in underlying free cash flow generation trajectory.

Acquisitions are limited by the balance sheet. ZBH’s leverage constrains transformative M&A. Bolt-on acquisitions in sports medicine or complementary orthopedic technologies are within reach; a large platform acquisition similar to the original Biomet transaction is not realistic in the current capital structure. This capital allocation constraint is one reason why the ROSA robotics execution strategy must succeed organically — ZBH cannot buy its way to a market-leading position the way a low-leverage balance sheet company could.

This capital allocation hierarchy — debt reduction first, then ROSA investment, then buybacks — means ZBH investors should calibrate expectations around buybacks. The primary investment thesis is business value creation through demographic volume growth and ROSA ASP lift, not financial engineering through capital return.

---

Tax Considerations for US Investors

Roth IRA: The demographic thesis behind ZBH is genuinely multi-decade. If you believe joint replacement demand will compound at low-to-mid single digits for the next 15-20 years — which the population data supports — then compounding that return inside a Roth IRA with no tax drag on appreciation or dividends is optimal. The modest ZBH dividend accrues tax-free inside a Roth; the capital appreciation from robotics-driven multiple expansion is fully sheltered.

Traditional 401k or IRA: Tax deferral still creates meaningful advantage for a long-duration investment. The consideration: ZBH gains realized inside a traditional account will be taxed as ordinary income at withdrawal. If you expect your retirement tax rate to be lower than your current marginal rate, the math favors traditional. If you’re in a lower bracket now and expect higher rates later, the Roth is better.

Taxable brokerage account: ZBH pays a qualified dividend taxed at preferential long-term capital gains rates. Capital gains on the stock itself qualify for long-term rates after a one-year holding period — 0%, 15%, or 20% depending on your income. Tax-loss harvesting opportunities arise during periods of Stryker outperformance (when ZBH underperforms relatively) — losses can offset gains elsewhere in your portfolio.

ETF route: XLV provides diversified healthcare exposure including ZBH; IHI provides purer medical device exposure. Both diversify away the ROSA-vs-Mako specific execution risk, but also dilute ZBH-specific upside if the robotics thesis plays out.

---

Earnings Call Checklist

Before each quarterly earnings report, focus your review on these seven variables:

• Knee reconstruction volume growth — US vs. international separately — Compare against Stryker’s reported volumes for the same period to assess relative share gains or losses
• ROSA new system placements in the quarter — And cumulative installed base — the trajectory is more important than any single quarter
• Hip reconstruction growth rate vs. knee — Hip has historically lagged; ROSA Hip adoption is earlier stage
• Adjusted operating margin (excluding amortization of intangibles) — True underlying profitability trend; the amortization from the Biomet merger still distorts GAAP margins
• China revenue and explicit management guidance on VBP impact — Watch for any admission that additional VBP rounds are included (or not) in the full-year guidance
• Free cash flow — Sufficient to fund share buybacks, debt service, and R&D reinvestment simultaneously?
• Management commentary on competitive dynamics vs. Mako — Listen specifically for whether they are citing won competitive conversions, or only defending existing share

---

Related Analysis

• Stryker (SYK) Stock Outlook 2026 — The benchmark and direct ROSA competitor
• Medtronic (MDT) Stock Outlook 2026 — Diversified device portfolio contrast
• Boston Scientific (BSX) Stock Outlook 2026 — Cardio-focused device compounder in a different anatomy
• Global Payments (GPN) Stock Outlook 2026 — Cyclical fintech contrast to ZBH’s defensive profile

---

Verdict: Demographics as the Floor, Robotics as the Ceiling

ZBH is best understood as a two-story investment thesis.

The ground floor — joint reconstruction volume growing reliably with aging populations — is stable, demographically anchored, and unlikely to disappoint materially over a multi-year hold. This floor does not require ZBH to win against Stryker, outgrow the market, or successfully execute on any ambitious strategic initiative. It requires only that ZBH maintain its existing commercial position in a growing market. That is not a demanding ask.

The second floor — ROSA closing the Mako gap and driving ASP lift above the demographic baseline — is where upside and risk concentrate simultaneously. If ROSA gains enough installed base traction that a meaningful percentage of ZBH cases shift to robotic procedures, the revenue per case rises and the stock can trade at a Stryker-like multiple. If Mako continues to deepen its lead, ZBH remains a permanent discount to its closest competitor.

The realistic base case sits between these floors: ROSA makes steady, unspectacular progress against Mako; procedure volumes grow at low-to-mid single-digit demographic rates; ZBH trades at a persistent but modest discount to Stryker. For a patient, long-duration investor, that is probably sufficient to generate reasonable compound returns — not spectacular, but rooted in a structural tailwind that is among the most durable in the US equity market.

The risk is not catastrophic. Nobody is going to cure osteoarthritis in the next decade. The floor is real. The question is always whether the ceiling is reachable — and the robotics competition will be the determining variable.

Disclaimer: This article is for informational purposes only and is not investment advice. Do your own research.